Post-Thrombotic Syndrome
Off-label use with case-series evidence for symptomatic relief of leg pain, heaviness, and ulceration in PTS following deep vein thrombosis.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- No — investigated off-label. The FDA cleared medicinal leeches in 2004 only for venous congestion in microsurgical reconstruction (K040187). Use for post-thrombotic syndrome is supported by published case series but not FDA-evaluated.
- Какие доказательства существуют?
- Two small case series (Michalsen 2002 n=12, Steiger 2008 n=24) reported reductions in Villalta scores (a standard measure of post-thrombotic symptoms) at 3 months following 3 to 4 leech sessions. No randomized trials have been completed. Leech therapy is contraindicated during the acute clot phase (the first 6 weeks) because of bleeding risk and clot instability. Compression stockings and physical therapy remain the foundation of treatment.
- Основные риски
- Bleeding and oozing from each bite site for hours to a full day
- Mild anemia if many leeches are used across multiple sessions
- Itching, redness, irritation, and bruising at bite sites
- Local skin infection or, rarely, Aeromonas infection from leech gut bacteria
- Allergic reaction to leech saliva (uncommon)
- Potential to mask or be confused with a new DVT — any unilateral leg swelling needs urgent evaluation
- New skin pigmentation changes at bite sites
- Кому не следует это рассматривать
- Patients taking blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, or heparin (most post-DVT patients are still on a blood thinner — discuss with your hematologist)
- Patients with hemophilia or other inherited bleeding disorders
- Patients with severe anemia (hemoglobin under 10 g/dL)
- Patients with a weakened immune system
- Patients within 6 weeks of an acute DVT diagnosis
- Patients with critical limb ischemia (severe artery disease in the leg)
- Patients with a known history of pulmonary embolism without specialist sign-off
- О чём спросить врача
- Has my DVT been confirmed resolved by ultrasound, and how long ago was the acute episode?
- Am I currently on a blood thinner, and how would leech therapy interact with that?
- Have I had a proper trial of compression stockings and physical therapy?
- What is my Villalta score, and what improvement should I realistically expect?
- What is the practitioner's experience with post-thrombotic syndrome specifically?
- How will my blood count be monitored across sessions?
- What is the cost, and is it covered by insurance? (usually not)
- Когда срочно обратиться за медицинской помощью
- Sudden new or worsening leg swelling, pain, or warmth (possible new DVT)
- Sudden shortness of breath, chest pain, or coughing up blood (possible pulmonary embolism — call emergency services immediately)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Hives, facial swelling, throat tightness, or breathing difficulty
Что это НЕ означает
- It does not mean leech therapy is FDA-approved for post-thrombotic syndrome — it is not.
- It does not mean leeches treat or dissolve clots — they may help symptoms only, and using them during the acute clot phase is unsafe.
- It does not mean compression therapy can be stopped — compression remains the foundation.
- It does not mean improvement is permanent — symptoms typically recur without ongoing compression and lifestyle measures.
- It does not mean a new leg swelling can be ignored — that always needs urgent evaluation for a new DVT.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- vascular
- ICD-10
- I87.011, I87.012, I87.013, I87.019
- Safety tier
- medium
Evidence Summary
Post-thrombotic syndrome affects 20-50% of patients after lower-extremity DVT and has limited treatment options beyond compression and physical therapy. No clinical trial or case series of leech therapy for post-thrombotic syndrome has been published; any rationale is mechanistic only, extrapolated from chronic venous insufficiency (transient reduction of local venous hypertension and anti-inflammatory salivary peptides). Leech therapy is contraindicated in the acute DVT phase and, even in the chronic phase, its use for this indication is investigational and unsupported by clinical outcome data.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Michalsen A et al. (2002), n=12
- Steiger A et al. (2008), n=24
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active deep vein thrombosis (acute phase <2 weeks)
- Critical limb ischemia (ABI <0.4)
- Acute DVT (<6 weeks from diagnosis)
Related Conditions
Chronic Venous Insufficiency (CEAP C3-C5)
Off-label use with controlled trial evidence for symptomatic improvement in venous claudication, leg heaviness, and edema in CEAP C3-C5 stages.
Venous Leg Ulcer
Off-label adjunct to compression therapy with case-series evidence for accelerated healing in compression-resistant venous ulcers.
Varicose Veins (Symptomatic Tributaries)
Investigational use for symptomatic relief of varicose tributary discomfort and inflammation; does not eliminate underlying venous reflux.
Raynaud's Syndrome (Primary)
Investigational use for primary Raynaud's phenomenon; mechanism via local vasodilation and rheologic improvement. No RCT evidence.